Search Results - "Zhang, Zufei"

A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam by Bhagunde, Pratik, Zhang, Zufei, Racine, Fred, Carr, Donna, Wu, Jin, Young, Katherine, Rizk, Matthew L.

“…•The impact of relebactam concentration on imipenem susceptibility is described.•The PK/PD driver for relebactam is fAUC/MIC.•A relebactam fAUC/MIC ratio of…”
Get full text

Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial by Shorr, Andrew F, Bruno, Christopher J, Zhang, Zufei, Jensen, Erin, Gao, Wei, Feng, Hwa-Ping, Huntington, Jennifer A, Yu, Brian, Rhee, Elizabeth G, De Anda, Carisa, Basu, Sumit, Kollef, Marin H

“…The randomized, double-blind, phase 3 ASPECT-NP trial evaluated the efficacy of 3 g of ceftolozane/tazobactam (C/T) versus 1 g of meropenem infused every 8 h…”
Get full text

Magmatic-hydrothermal evolution of the Dangba rare-metal granitic pegmatites in the Songpan–Ganzê orogenic belt, Eastern Tibet: Insights from muscovite and columbite-group minerals by Xu, Lin, Chen, Lei, Zhao, Jingyu, Li, Jie, Wang, Shuilong, Yang, Wenguo, Li, Jian, Yang, Bo, Wang, Hai, Yang, Yongsheng, Zhang, Zufei, Lu, Wenning

“…Rare-metal granitic pegmatites are commonly considered to be the results of a combination of magmatic and hydrothermal processes. Although magmatic…”
Get full text

Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes by Zhang, Zufei, Farooq, Muhammad, Prasad, Bhagwat, Grepper, Sue, Unadkat, Jashvant D

“…In pregnant women, CYP3A activity increases by 100% during the third trimester (T3). Due to logistical and ethical constraints, little is known about the…”
Get full text

Effect of Salt Intake on Bioavailability of Mizoribine in Healthy Japanese Males by Ishida, Kazuya, Fukao, Miki, Watanabe, Hitomi, Taguchi, Masato, Miyawaki, Toshio, Matsukura, Hiroyoshi, Uemura, Osamu, Zhang, Zufei, Unadkat, Jashvant D., Hashimoto, Yukiya

“…Bioavailability of mizoribine in subjects with the concentrative nucleoside transporter 1 (CNT1, SLC28A1) 565-A/A allele is significantly lower than that in…”
Get full text

Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs by Zhang, Zufei, Unadkat, Jashvant D

“…Fetal exposure to drugs cannot be readily estimated from single time point cord blood sampling at the time of delivery. Therefore, we developed a…”
Get full text

Time‐varying brentuximab vedotin pharmacokinetics and weight‐based dosing in paediatric patients despite lower exposure in those aged 2 to <6 and 6–11 years by Zhang, Daping, Zhang, Zufei, Lee, Anthony, Fenton, Keenan, Jain, Shweta, Garg, Amit, Chia, Yen Lin

“…Aims We studied the pharmacokinetics and exposure–response relationships of the brentuximab vedotin (BV) antibody–drug conjugate (ADC) and unconjugated…”
Get full text

Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses by Zhang, Zufei, Imperial, Marjorie Z, Patilea-Vrana, Gabriela I, Wedagedera, Janak, Gaohua, Lu, Unadkat, Jashvant D

“…Determining fetal drug exposure (except at the time of birth) is not possible for both logistical and ethical reasons. Therefore, we developed a novel…”
Get full text

Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP) by Huntington, Jennifer A, Yu, Brian, Li, Linping, Jensen, Erin, Bruno, Christopher, Boakye, Mathew, Zhang, Zufei, Gao, Wei, Feng, Hwa-Ping, Rhee, Elizabeth

“…In the phase 3 ASPECT-NP trial (NCT02070757), ceftolozane/tazobactam (C/T) was noninferior to meropenem for treatment of Gram-negative ventilated…”
Get full text

A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment by Tatosian, Daniel A., Yee, Ka Lai, Zhang, Zufei, Mostoller, Kate, Paul, Erina, Sutradhar, Santosh, Larson, Patrick, Chhibber, Aparna, Wen, Jianzhong, Wang, Ya‐Juan, Lassman, Michael, Latham, Andrew H., Pang, Jianmei, Crumley, Tami, Gillespie, Anne, Marricco, Nadia Cardillo, Marenco, Ted, Murphy, Matthew, Lasseter, Kenneth C., Marbury, Thomas C., Tweedie, Donald, Chu, Xiaoyan, Evers, Raymond, Stoch, S. Aubrey

“…Renal impairment (RI) is known to influence the pharmacokinetics of nonrenally eliminated drugs, although the mechanism and clinical impact is poorly…”
Get full text

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects by Rizk, Matthew L, Rhee, Elizabeth G, Jumes, Patricia A, Gotfried, Mark H, Zhao, Tian, Mangin, Eric, Bi, Sheng, Chavez-Eng, Cynthia M, Zhang, Zufei, Butterton, Joan R

“…This phase I study assessed the intrapulmonary pharmacokinetic profiles of relebactam (MK-7655), a novel β-lactamase inhibitor, and imipenem. Sixteen healthy…”
Get full text

Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma by Zhang, Zufei, Zhang, Daping, Guo, Wenchuan, Fenton, Keenan, Narayanan, Sujata, Jain, Shweta, Jiang, Joy, Castellino, Sharon M, Kelly, Kara M, Cole, Peter D, Keller, Frank G, Garg, Amit, Chia, Yen Lin

“…The purpose of the study was to evaluate the relationships between brentuximab vedotin (BV) pharmacokinetics, age, and body weight (BW) with efficacy and…”
Get full text

Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia by Zhang, Zufei, Patel, Yogesh T., Fiedler‐Kelly, Jill, Feng, Hwa‐Ping, Bruno, Christopher J., Gao, Wei

“…Ceftolozane/tazobactam (C/T) is a combination of a novel cephalosporin with tazobactam, recently approved for the treatment of hospital‐acquired and…”
Get full text

Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP by Gao, Wei, Passarell, Julie, Patel, Yogesh T, Zhang, Zufei, Lin, Gina, Fiedler-Kelly, Jill, Bruno, Christopher J, Rhee, Elizabeth G, De Anda, Carisa S, Feng, Hwa-Ping

“…An exposure-efficacy analysis of the phase 3 ASPECT-NP trial was performed to evaluate the relationship between plasma exposure of ceftolozane and tazobactam…”
Get full text

Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia by Gao, Wei, Patel, Yogesh T., Zhang, Zufei, Johnson, Matthew G., Fiedler‐Kelly, Jill, Bruno, Christopher J., Rhee, Elizabeth G., Anda, Carisa De, Feng, Hwa‐Ping

“…Probability of target attainment (PTA) analyses were conducted to support the recommended ceftolozane/tazobactam dosing regimens, adjusted for renal function,…”
Get full text

616: OUTCOMES IN PATIENTS WITH AUGMENTED RENAL CLEARANCE TREATED WITH CEFTOLOZANE-TAZOBACTAM IN ASPECT-NP by Shorr, Andrew, Bruno, Christopher, Zhang, Zufei, Jensen, Erin, Gao, Wei, Feng, Hwa-Ping, Huntington, Jennifer, Yu, Brian, Rhee, Elizabeth, De Anda, Carisa, Kollef, Marin

Get full text

Prediction of the Magnitude of Induction of CYP3A Activity during Early Human Pregnancy by Zhang, Zufei, Farooq, Muhammad, Grepper, Sue, Unadkat, Jashvant

“…Abstract only Background In pregnant women, CYP3A activity increases by ~2 fold during the third trimester (T3) [1]. Due to logistical and ethical constraints,…”
Get full text

Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia and End‐Stage Renal Disease Receiving Intermittent Hemodialysis by Feng, Hwa‐Ping, Patel, Yogesh T., Zhang, Zufei, Fiedler‐Kelly, Jill, Bruno, Christopher J., Rhee, Elizabeth G., De Anda, Carisa, Gao, Wei

“…ASPECT‐NP, a phase 3 trial of ceftolozane/tazobactam in hospital‐acquired/ventilator‐associated bacterial pneumonia (HABP/VABP), excluded patients with…”
Get full text

PREDICTING FETAL EXPOSURE TO DRUGS THROUGHOUT PREGNANCY USING A PBPK MODEL by Zhang, Zufei, Imperial, Marjorie Z., Patilea‐Vrana, Gabriela I., Wedagedera, Janak, Lu, Gaohua, Unadkat, Jashvant D.

“…Background Pregnant women use medication throughout pregnancy [1]. As a result, their fetuses are de facto exposed to drugs. For logistical and ethical…”
Get full text

Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis by Arrieta, Antonio C., Ang, Jocelyn Y., Zhang, Zufei, Larson, Kajal B., Yu, Brian, Johnson, Matthew G., Rhee, Elizabeth G., Feng, Ed H., Rizk, Matthew L.

“…Background The antipseudomonal cephalosporin/β‐lactamase inhibitor combination ceftolozane/tazobactam could be a potential treatment option for cystic fibrosis…”
Get full text